Complications Associated with RSV Infections

Increasing knowledge of the vaccine-preventable disease will ultimately improve vaccine uptake among target groups, researchers suggest.

Vaccination against seasonal influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure was found safe with low incidence of mild adverse events (AEs).

The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.

Respiratory syncytial virus (RSV) hospitalization–related features may help inform prevention approaches among children with the infection, according to one study.

The FDA approved mRNA-1345, a Moderna vaccine for the treatment of respiratory syncytial virus (RSV). This single-dose vaccine offers protection against lower respiratory tract disease in adults over 60 years, with data suggesting long-term effectiveness.

Lung sound analysis was able to confirm airway narrowing in patients with respiratory syncytial virus (RSV) acute bronchiolitis.